News
INO
1.130
+1.80%
0.020
Weekly Report: what happened at INO last week (0615-0619)?
Weekly Report · 1d ago
Weekly Report: what happened at INO last week (0608-0612)?
Weekly Report · 06/15 09:53
Weekly Report: what happened at INO last week (0601-0605)?
Weekly Report · 06/08 09:50
Inovio Pharmaceuticals Inc. Stock Falls 5.8%, Underperforms Peers
Dow Jones · 06/03 20:34
Inovio Pharmaceuticals Inc. Stock Falls 5.5%, Underperforms Peers
Dow Jones · 06/02 20:35
Inovio Pharma Is Maintained at Neutral by HC Wainwright & Co.
Dow Jones · 06/01 11:10
Inovio Pharma Price Target Cut to $2.50/Share From $3.00 by HC Wainwright & Co.
Dow Jones · 06/01 11:10
HC Wainwright & Co. Maintains Neutral on Inovio Pharmaceuticals, Lowers Price Target to $2.5
Benzinga · 06/01 11:00
Inovio price target lowered to $2.50 from $3 at H.C. Wainwright
TipRanks · 06/01 10:38
Weekly Report: what happened at INO last week (0525-0529)?
Weekly Report · 06/01 09:53
Inovio Pharmaceuticals Inc. Stock Slips 6.7%, Underperforms Peers
Dow Jones · 05/26 20:33
Inovio Pharmaceuticals Shareholders Back Board as INO-3107 FDA Review Advances
NASDAQ · 05/25 18:02
Weekly Report: what happened at INO last week (0518-0522)?
Weekly Report · 05/25 09:55
Inovio gains on late-stage trial win for DNA shot
Seeking Alpha · 05/22 16:35
Analysts Are Bullish on These Healthcare Stocks: Inovio Pharmaceuticals (INO), Vera Therapeutics (VERA)
TipRanks · 05/22 11:20
Inovio Pharmaceuticals Inc. Stock Advances 8.1%, Outperforms Peers
Dow Jones · 05/21 20:33
Inovio: ApolloBio announces ‘positive’ results from Phase 3 trial of VGX-3100
TipRanks · 05/21 20:21
Inovio Pharmaceuticals' Partner For VGX-3100 In China, ApolloBio, Announces Topline Results From Its Pivotal Phase 3 Trial Of VGX-3100; Trial Met Its Predefined Primary Efficacy Endpoint And Demonstrated An Overall Favorable Safety And Tolerability Profile
Benzinga · 05/21 20:09
Inovio partner ApolloBio says VGX-3100 Phase 3 cervical dysplasia trial hits endpoint
PUBT · 05/21 20:06
INOVIO PHARMACEUTICALS INC - VGX-3100 PHASE 3 TRIAL MEETS PRIMARY ENDPOINT WITH FAVORABLE SAFETY PROFILE
Reuters · 05/21 20:05
More
Webull provides a variety of real-time INO stock news. You can receive the latest news about Inovio Pharmaceu through multiple platforms. This information may help you make smarter investment decisions.
About INO
Inovio Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from human papillomavirus (HPV)-related diseases, cancer, and infectious diseases. Its proprietary investigational CELLECTRA devices are designed to deliver the plasmids into the body’s cells for optimal effect, without the use of chemical adjuvants, lipid nanoparticles or viral vectors. Its lead candidate is INO-3107 for the treatment of recurrent respiratory papillomatosis (RRP), a chronic, rare and debilitating disease caused by HPV-6 and HPV-11. Its DNA medicines in the pipeline include INO-3112 for the Treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, VGX-3100 for the Treatment of HPV-related Cervical HSIL, VGX-3100 for the Treatment of Anal or Perianal HSIL, INO-5401 for the Treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Prevention of Cancer for People with BRCA1/2 Mutation.